High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients

Pediatric Hematology and Oncology

Volumn 28, Issue 2, 2011, Pages 115-123

  Molina, Blanca ^a   Alonso, Laura ^a   Gonzalez Vicent, Marta ^a   Andion, Maitane ^a   Hernandez, Carmen ^a   Lassaletta, Alvaro ^a   Cormenzana, Maria ^a   Lopez Ibor, Blanca ^b   Villa, Marta ^b   Molina, Javier ^c   Diaz, Miguel A ^a,b  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b Hospital Madrid Monteprincipe   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

autologous PBPC transplantation; busulfan and melphalan; neuroblastom

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VINCRISTINE;

ADOLESCENT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; ENGRAFTMENT SYNDROME; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NEUROBLASTOMA; NEUTROPHIL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW NEOPLASMS; BONE NEOPLASMS; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INFANT; LIVER NEOPLASMS; MALE; MELPHALAN; NEOPLASM STAGING; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79751508332     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.537434     Document Type: Article

References (28)

1. Matthay KK, Villablana JG, Seeger RC, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N Eng J Med. 1999;341:1165-1173. (Pubitemid 29480654)
2. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649-658. (Pubitemid 41222755)
3. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348-357. (Pubitemid 40316027)
4. Ladenstein R, Pottschger U, Hartman O, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant. 2008;41:S118-S127. (Pubitemid 351864722)
5. Diaz MA, Vicent MG, Madero L. High dose busulfan-melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumours. Bone Marrow Transplant. 1999;24:1157-1159. (Pubitemid 30021206)
6. Canete A, Gerrard M, Rubie H, et al. Poor survival for infants with MYCN amplifed metastatic neuroblastoma despite intensifed treatment: the International Society ofPaediatric European Neuroblastoma experience.J Clin Oncol. 2009;27:1014-1019.
7. Diaz MA, Villa M, Alegre A, et al. Collection and transplantation ofperipheral blood progenitor cells mobilized by G-CSF alone in children with malignancies. Br J Haematol. 1996;94:148-154. (Pubitemid 26232557)
8. Diaz MA, Alegre A, Villa M, et al. Pediatric experience with autologous peripheral blood progenitor cell transplantation: infuence ofCD34+ cell dose in engraftment kinetics. Bone Marrow transplant. 1996;18:699-703. (Pubitemid 26361356)
9. Diaz MA, Garcia-Sanchez F, Lillo R, et al. Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell counts predicts progenitor cell yield. Haematologica. 1999;84:30-33.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Asoc. 1958;53:457-481.
11. Cox DR. Regression models and life tables.JRStat Soc. 1972;34:187-220.
12. Flandin I, Hartmann O, Michon J, et al. Impact of TBI on late efects in children treated by megatherapy for stage IV neuroblastoma. A study for the French Society of Pediatric Oncology. Int J Radiat Oncol Biol Phys. 2006;64:1424-1431.
13. Hobbie WL, Moshang T, Carlson CA, et al. Late efects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer. 2008;51:679-683.
14. Yalcin B, Kremer LC, Caron HN, van Dalen EC High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high risk neuroblastoma. Cochrane Database Syst Rev. 2010;(5):CD006301.
15. Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008;41:159-165. (Pubitemid 351188913)
16. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumour Registry. J Clin Oncol. 1998;16:953-965. (Pubitemid 28108728)
17. Park RJ, Villablanca JG, London WB, et al. Outcome ofhigh riskstage3 neuroblastomawith myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer2009;52:44-50.
18. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial ofmyeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study.J Clin Oncol. 2009;27:1007-1013.
19. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell supported transplantation: long-term survival update.J Clin Oncol. 2006;24:2891-2896. (Pubitemid 46630591)
20. Grupp SA, Stem JW, Bunin N, et al. Tandem High-dose therapy in rapid sequence for children with high-riskneuroblastoma.J Clin Oncol. 2000;18:2567-2575. (Pubitemid 30432523)
21. Cohn SL, Pearson ADJ, London WB, et al. Te International Neuroblastoma Risk Group (INRG) Classifcation System: an INRG Task Force report.J Clin Oncol. 2009;27:289-297.
22. Hartmann O, Valteu-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999;23:789-795. (Pubitemid 29186889)
23. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243-2253. (Pubitemid 41697287)
24. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic patterns is a predictor of outcome in neuroblastoma.J Clin Oncol. 2009;27:1026-1033.
25. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozigosity at 1p 36 independentlypredicts for disease progression but not decrease overall survival probability in neuroblastoma patients: a Children's Cancer Group study.J Clin Oncol. 2000;18:1888-1899. (Pubitemid 30261926)
26. Caron H, Van Sluis P, Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patientswith neuroblastoma. N Engl J Med. 1996;334:225-230. (Pubitemid 26030673)
27. Gehring M, Berthold F, Edler L, et al. Te 1p deletion is not a reliable marker for the prognosis of patientswith neuroblastoma. Cancer Res. 1995;55:5366-5369.
28. Venstrom JM, Zheng J, Noor N, et al. KIRand HLAgenotypes are associates with disease progression and survival following autologous hematopoietic stem cell transplantation for high risk neuroblastoma. Clin Cancer Res. 2009;15:7330-7334.